Fig. 5: Navitoclax treatment selects pre-existing resistant clones. | npj Breast Cancer

Fig. 5: Navitoclax treatment selects pre-existing resistant clones.

From: Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations

Fig. 5

a The number of common unique barcodes between baseline, post-treatment cycle 1, and post-treatment cycle 2 samples. b The number of new and existing clones that increased in abundance as detected at end of each cycle: Cycle 1— Post 1st treatment versus Baseline; Cycle 2— Post 2nd treatment versus Post 1st treatment. c The distribution of barcodes divided into the 5 subgroups defined in panel a, shows a considerable decrease in barcode complexity after treatment. Groups are labeled by a sequence of three numbers representing inclusion (1) or exclusion (0) in the baseline, post-cycle 1, and post-cycle 2 samples. d Clonal evolution of cancer cells estimated by the observed barcode prevalence weighted by the abundance of each barcode.

Back to article page